MorphoSys AG — Board/Management Information 2004

May 12, 2004

News Details

Corporate | 12 May 2004 07:46

MorphoSys Appoints New Supervisory Board Member

Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– Martinsried/Munich, May 12, 2004 MorphoSys Appoints New Supervisory Board Member MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the Company’s shareholders confirmed the appointment of Dr. Metin Colpan to the MorphoSys supervisory board at the Company’s annual shareholder meeting yesterday. Dr. Colpan was co-founder, Chief Executive Officer and Managing Director of QIAGEN for nearly 20 years, where he successfully led the company to its position as one of the leading global life sciences companies. Dr. Colpan replaces Dr. Jörg Reinhardt, Director of Development and member of the Executive Committee at Novartis Pharma. In addition to the confirmation of Dr. Colpan’s appointment to the supervisory board, all other management proposals of the shareholder assembly agenda were passed with large majorities at the meeting in Munich. “We are very pleased that Dr. Colpan has joined our board”, commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. “Dr. Colpan’s experience in building QIAGEN into one of the world’s leading biotechnology companies will be invaluable for MorphoSys to foster our new business initiative in the reagent field, Antibodies by Design.” Dr. Reinhardt joined the Supervisory Board of MorphoSys in July 2001 and refrained from seeking re-election due to increased other commitments. During his term with MorphoSys Dr. Reinhardt played a prominent role in the formulation of the Company’s strategy. “I want to thank Dr. Reinhardt for his invaluable support and commitment to MorphoSys during his term on our board. His expertise in drug development and extensive knowledge of the pharmaceutical industry have proved to be substantial assets. He has made an enormous contribution to the successful development of the Company”, commented Dr. Moroney. About MorphoSys: MorphoSys develops and applies technologies for the production of synthetic antibodies, which accelerate drug discovery and disease-related target molecules. The Company was founded in 1992 and has a wide range of innovative technologies, above all HuCAL(R), the Human Combinatorial Antibody Library, which is used by researchers worldwide for human antibody generation. The Company has collaborations with international pharmaceutical companies such as Bayer (Berkeley, California/USA), Biogen Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Martinsried/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). Further information can be found on the Company’s website: http://www.morphosys.com . Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering. For more information, please contact MorphoSys: Dave Lemus Chief Financial Officer Tel: +49 (0) 89 / 899 27-439 Fax: +49 (0) 89 / 899 27-5439 investors@morphosys.com Dr. Claudia Gutjahr-Löser Mario Brkulj Director Corporate Communications PR Specialist Tel: +49 (0) 89 / 899 27-122 Tel: +49 (0) 89 / 899 27-454 Fax: +49 (0) 89 / 899 27-5122 Fax: +49 (0) 89 / 899 27-5454 gutjahr-loeser@morphosys.com brkulj@morphosys.com end of message, (c)DGAP 12.05.2004 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 120746 Mai 04